Greenland Mines Subsidiary Major Precious Greenland A/S Joins Greenland Business Association
PRNewswire (Thu, 2-Apr 12:01 PM ET)
Greenland Mines Delays Annual 10-K Filing
TipRanks (Wed, 1-Apr 2:25 PM ET)
Greenland Mines Secures Icebreaker Argus For 2026 Skaergaard Field Program
PRNewswire (Wed, 25-Mar 8:00 AM ET)
Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance
PRNewswire (Mon, 23-Mar 8:00 AM ET)
PRNewswire (Thu, 19-Mar 12:05 PM ET)
PRNewswire (Thu, 12-Mar 10:28 AM ET)
Greenland Mines Ltd operates in two divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland, an undeveloped palladium, gold, and platinum deposit; and 2) Cell and Gene Therapy, which focuses on the development of biologic, cell, and gene therapies for neurodegenerative and age-related disorders, including Alzheimer's, amyotrophic lateral sclerosis (ALS), Parkinson's, and related conditions, targeting areas of high unmet medical need.
Greenland Mines trades on the NASDAQ stock market under the symbol GRML.
As of April 2, 2026, GRML stock price declined to $0.36 with 2,048,261 million shares trading.
GRML has a market cap of $44.14 million. This is considered a Sub-Micro Cap stock.
GRML support price is $.33 and resistance is $.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRML shares will trade within this expected range on the day.